In an industry as dynamic and competitive as healthcare, standing out requires outstanding ingenuity, while still maintaining a dedication to patient wellbeing and care. For California-headquartered biopharmaceutical company Amgen, which last year celebrated 40 years of providing innovative and life-changing treatments to patients, being a leader is baked into its DNA. Over that period, 70%…

Research-based biopharmaceutical multinational AstraZeneca, one of the earliest healthcare companies to enter the Taiwan market, has been working to deliver the best in patient care in Taiwan for over 70 years. The company’s dedication to advancing medical science is reflected in its innovation and outstanding performance in R&D. It is also focused on “beyond the…

Finding effective solutions to the world’s health issues requires novel, holistic approaches and collaborative ingenuity. Healthcare companies must therefore increasingly shift their focus to the research and development of medical technologies, biopharmaceuticals, and innovative therapies to treat conditions and diseases that are difficult or nearly impossible to tackle using traditional medicines. Such a reality is…

2020 has been a big year for American biopharmaceutical company Bristol Meyers Squibb (BMS). Its blockbuster US$74 billion acquisition last year of biotech firm Celgene positions BMS as the number one oncology hematology company worldwide. What this merger means for the Taiwan BMS affiliate is not only a portfolio expansion, doubling the number of key…

2020 has been an extraordinarily challenging year for people, governments, and companies around the world. For biopharma multinational Amgen, which this year turns 40, and its Taiwan affiliate, now in its fifth year of operation on the island, 2020 has become a time for reflection. As different countries experience varying levels of disruption and negative…

Pfizer has called on the biopharmaceutical industry to join the company in committing to unprecedented collaboration to combat COVID-19. “In this troubling time, Pfizer is committed to doing all we can to respond to the COVID-19 pandemic,” Dr. Albert Bourla, the company’s Chairman and CEO, said in a statement. “Many companies, including Pfizer, are working…

Taiwan is making great strides in developing its biotech sector, but reaching the NT$ trillion mark in annual production value by 2025 won’t be easy. When the Biotech Innovation Organization (BIO), the world’s leading industry association for biotechnology, chose to hold its annual regional conference this summer in Taipei, it was a big boost for…

Transforming Taiwan into a regional biomedical hub will require some creativity. Taiwan’s biomedicine industry has many of the ingredients for success. The island has strong scientific talent, rich clinical-trial experience, abundant capital, a treasure trove of medical data (from the National Health Insurance system), information-technology expertise, and strong intellectual property rights protection bolstered by the…